HEM Pharma Inc.'s Largest Shareholder Yoseb Ji Reports Slight 0.07%p Stake Decrease Due to Executive Stock Option Exercise; Minimal Capital Inflow, Limited Impact on Shareholder Value
According to the substantial shareholding report filed by HEM Pharma Inc.'s largest shareholder Yoseb Ji, the total outstanding shares increased by 23,000 shares due to the exercise of stock options by executive Kim Bong-jun, resulting in a slight decrease in the reporting group's ownership from 26.72% to 26.65%, a drop of 0.07 percentage points.
The exercise price of the stock options was 14,590 KRW, a 71% discount to the current market price of 51,000 KRW, but with only 6,000 shares exercised, the capital inflow to the company was approximately 87.54 million KRW, making the financial impact negligible.
The reporter expressed his intention to continue exercising control over management as the largest shareholder, and the report does not include any events that would dilute shareholder value such as new capital raising or convertible bond issuance.
[AI Summary]This disclosure reflects a minor change in shareholding due to a small-scale executive stock option exercise. The increase in total shares outstanding is only 0.32%, which is unlikely to have a significant impact on stock price or shareholder value. The largest shareholder's control remains stable, and short-term dilution risk is limited.